The announcement of an upsized public offering and the issuance of pre-funded warrants by TScan Therapeutics could lead to dilution of existing shares, which might negatively impact the stock price in the short term. However, the capital raised could be beneficial for the company's growth and development projects, indicating a mixed impact but with a short-term negative bias due to the immediate dilution concern.